Beware: Fake IBRANCE Medications Are Circulating, Putting Lives at Risk! The World Health Organization (WHO) has issued an urgent alert regarding multiple batches of counterfeit IBRANCE (palbociclib) that have been uncovered across several countries, including Côte d’Ivoire, Egypt, Lebanon, Libya, and Türkiye. These fake products, reported to WHO in November 2025, are not only sold directly to consumers through online platforms but have also been found stocked at some pharmacies—posing a serious danger to patients relying on this cancer treatment.
IBRANCE (palbociclib) is a critical oral medication prescribed for treating certain forms of advanced breast cancer. Genuine IBRANCE capsules contain active pharmaceutical ingredients that target cancer cells effectively. However, the falsified versions identified contain no active ingredient at all, rendering them completely ineffective and potentially life-threatening. Without the proper medicinal compound, patients risk uncontrolled disease progression and a much higher chance of mortality.
Here’s where it gets controversial... The counterfeit products are cleverly disguised, falsely representing their identity, ingredients, and manufacturer details. The legitimate producers have verified that these products are fake after testing samples which contained zero active drug. Additionally, careful examination revealed visual inconsistencies on the packaging, including irregular capsule markings and poor printing quality. Shockingly, some counterfeits even bear authentic lot numbers, which further complicates detection.
How to spot fake IBRANCE:
- Watch out for certain falsified lot numbers that do not exist in authentic IBRANCE: FS5173, GS4328, LV1850, and TS2190.
- Be cautious with suspicious lots such as GK2981, GR6491, GT5817, HJ8710, and HJ8715, especially if other irregular signs are present.
- Check the label for mistakes like the phrase “Manufactured by: Pfizer, PO Box 29387, Mission, KS 66201,” which should raise red flags.
- Look for spelling errors and substandard printing quality on the packaging.
- The security foil on the bottle might show the Pfizer logo printed in black ink, which is unusual.
- Capsules may be marked with black ink reading “PBC 125” or they might be completely unmarked.
- Capsule coloration could be off, such as an unusual bright orange hue.
The use of these counterfeit medicines is not just ineffective—it can cause catastrophic treatment failure and endanger lives. This issue demands immediate attention from healthcare workers, pharmacists, regulatory authorities, and patients themselves. If you encounter any adverse effects, a lack of expected treatment response, or notice suspicious packaging, report it without delay to your National Regulatory Authority or Pharmacovigilance Centre.
WHO strongly urges all involved in healthcare and regulation to enhance monitoring efforts especially in regions vulnerable to these falsified medicines. Vigilance should extend to informal and online markets where these products appear frequently. Law enforcement and health authorities must promptly inform WHO upon discovering counterfeit IBRANCE in their jurisdictions.
If you or someone you know may have received these falsified products, stop usage immediately and seek professional medical advice. For safety, always obtain medicines from licensed and authorized sources.
Have you, your healthcare provider, or pharmacy encountered strange or suspicious IBRANCE products? What steps do you think should be taken globally to prevent such dangerous fakes from reaching patients? Share your experiences or opinions below to help raise awareness and spark a crucial conversation about pharmaceutical safety.
For any information regarding the origin or distribution of these counterfeit medicines, please contact WHO directly at rapidalert@who.int.
For detailed product information and an official list of affected batches, refer to the WHO Medical Product Alert N°7/2025 document here.
